Paper aims to explore questions surrounding cytoreductive nephrectomy
June 4th 2024"Despite the results of SURTIME and CARMENA, among others, we continue to hear discussions about the role of cytoreductive nephrectomy in conferences and literature, suggesting that this remains a question that has not been fully addressed," says Jaleh Fallah, MD.
Dr. Merchan on findings from biomarker analyses of the CLEAR trial in RCC
June 3rd 2024“The results of the study showed that regardless of any biomarkers, the combination of pembrolizumab and lenvatinib was superior or associated with a better median progression-free survival compared to sunitinib,” says Jaime R. Merchan, MD.
Dr. Grünwald on progression patterns in advanced renal cell carcinoma
June 2nd 2024“So, we split this apart and looked into if the type of progression would occur differently depending on the organ sites, which it did not. What we have seen is maintained benefits for the combination of lenvatinib and pembrolizumab vs sunitinib,” says Viktor Grünwald, MD, PhD.
Dr. Fallah discusses recent research on cytoreductive nephrectomy
May 31st 2024"Our study looked at data from 5 trials of the combination therapy with an immune checkpoint inhibitor and the VEGF TKI evaluating if there's still any potential role for cytoreductive nephrectomy that is worth being investigated in prospective studies," says Jaleh Fallah, MD.
What does holistic review of urology resident applicants entail?
Published: May 30th 2024 | Updated: May 30th 2024"Holistic review is a way to assess an applicant's candidacy for residency by looking at lived experiences and personal attributes in addition to traditional metrics, like Step 1 scores, AOA, and number of research publications," says Alexandra Tabakin, MD.
Joy Maulik, CRNP, on the role of APPs in urologic care
May 29th 2024“Variation is the enemy of quality. The more streamlined we can do these things and include APPs in the teachings of procedures and understanding different subspecialties of prostate cancer, I think it would be helpful,” says Joy Maulik, CRNP
Dr. Murray on the current state of care in upper tract urothelial carcinoma
May 28th 2024“One of the biggest things that this brings us to for an update of upper tract disease is biopsy alone of an upper tract tumor is not good enough anymore--we must risk stratify these patients,” says Katie S. Murray, DO.
Dr. Bukavina on GLP1R agonists and genitourinary cancers
May 23rd 2024"Our first question is, in patients who were on the GLP1R agonists for a prolonged period of time, were those patients at increased or decreased risk of developing the most common GU malignancies?" says Laura Bukavina, MD, MPH.
Dr. Narayan discusses 5-year data on nadofaragene firadenovec in NMIBC
May 22nd 2024"The other was that we found that about half of the patients in the CIS cohort and two-thirds of those in the Ta/T1 or papillary cohort had bladder preservation, meaning they were able to avoid cystectomy," says Vikram M. Narayan, MD.
Investigators examine nationwide variations in genomic expression profiles in prostate cancer
May 21st 2024"We saw that Black men within this cohort had lower Decipher scores across all ages and Gleason scores different than what had been reported in other data sets, which was interesting," says Samuel L. Washington III, MD, MAS.
Dr. Soon-Shiong highlights efforts to increase access to N-803 in NMIBC
May 20th 2024“But more importantly, there are patients who have no insurance, there are patients who have no other resources and are maybe even on the poverty line. We feel, importantly, that we have an obligation that the drug be made free for these patients in the United States,” says Patrick Soon-Shiong, MD.